The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The price of Cabaletta Bio Inc (NASDAQ: CABA) closed at $11.01 in the last session, down -9.61% from day before closing price of $12.18. In other words, the price has decreased by -$9.61 from its previous closing price. On the day, 2.92 million shares were traded. CABA stock price reached its highest trading level at $12.3 during the session, while it also had its lowest trading level at $10.99.
Ratios:
We take a closer look at CABA’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 15.29 and its Current Ratio is at 15.29. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Jefferies on February 05, 2024, initiated with a Buy rating and assigned the stock a target price of $36.
On November 29, 2023, William Blair started tracking the stock assigning a Outperform rating and target price of $38.
On October 24, 2023, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $40.Cantor Fitzgerald initiated its Overweight rating on October 24, 2023, with a $40 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jan 19 ’24 when Binder Gwendolyn sold 11,000 shares for $19.59 per share. The transaction valued at 215,439 led to the insider holds 20,000 shares of the business.
Binder Gwendolyn sold 11,000 shares of CABA for $240,789 on Dec 19 ’23. The insider now owns 20,000 shares after completing the transaction at $21.89 per share. On Nov 20 ’23, another insider, Binder Gwendolyn, who serves as the insider of the company, sold 11,000 shares for $17.82 each. As a result, the insider received 196,014 and left with 20,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CABA now has a Market Capitalization of 531222592 and an Enterprise Value of 294909184.
Stock Price History:
The Beta on a monthly basis for CABA is 2.48, which has changed by -0.034210503 over the last 52 weeks, in comparison to a change of 0.22363698 over the same period for the S&P500. Over the past 52 weeks, CABA has reached a high of $26.35, while it has fallen to a 52-week low of $7.77. The 50-Day Moving Average of the stock is -41.68%, while the 200-Day Moving Average is calculated to be -36.26%.
Shares Statistics:
According to the various share statistics, CABA traded on average about 989.83K shares per day over the past 3-months and 1276980 shares per day over the past 10 days. A total of 47.82M shares are outstanding, with a floating share count of 37.98M. Insiders hold about 18.86% of the company’s shares, while institutions hold 88.40% stake in the company. Shares short for CABA as of 1713139200 were 9873052 with a Short Ratio of 9.97, compared to 1710460800 on 7090928. Therefore, it implies a Short% of Shares Outstanding of 9873052 and a Short% of Float of 21.149999.
Earnings Estimates
The market rating of Cabaletta Bio Inc (CABA) is currently shaped by the ongoing analysis conducted by 10.0 analysts closely monitoring its performance.On average, analysts expect EPS of -$0.48 for the current quarter, with a high estimate of -$0.31 and a low estimate of -$0.66, while EPS last year was -$0.45. The consensus estimate for the next quarter is -$0.47, with high estimates of -$0.3 and low estimates of -$0.61.
Analysts are recommending an EPS of between -$1.25 and -$2.29 for the fiscal current year, implying an average EPS of -$1.9. EPS for the following year is -$2.09, with 11.0 analysts recommending between -$0.94 and -$2.84.
